Drugs / Lutetium Lu 177 Dotate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04543955 Background | Sep 2021 → Jun 2022 | neuroendocrine neoplasm | Lowell Anthony, MD | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutetium Lu 177 Dotate | “Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses.” NCT04543955 ↗ |
| Known as | Lutathera | “Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses.” NCT04543955 ↗ |
| Route | Intravenous | “Lutetium Lu 177 Dotate (Lutathera) by IV” NCT04543955 ↗ |